Malaria

TOKYO, April 22, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately JPY 679 million (USD 4.5 million1) for the development of diagnostics for tuberculosis, in addition to an investment of approximately JPY 15.9 million (USD 0.1 million1) for a drug discovery project for Chagas disease and leishmaniasis.2 Investment of approximately JPY 679 million ( USD 4.5 million 1 ) for the development of diagnostics for tuberculosis Tuberculosis (TB) remains a serious infectious disease, with approximately 10.8 million cases and 1.25 million deaths reported in 2023, making it the leading causes of death from a single infectious agent.3 The United Nations' Sustainable Development Goals (SDGs) set a target to end TB by 2030, but achieving this goal requires accurate and accessible diagnostic technologies. Current TB tests face challenges such as low sensitivity, high costs, complexity, and the need for specialized equipment and sputum samples, making them unsuitable for all patients. In particular, children, people with conditions who cannot produce sputum, and those in resource-limited settings often struggle to receive timely diagnoses, causing the continued spread of the disease. To address this issue, the GHIT Fund has decided to invest approximately JPY 679 million (USD 4.5 million1) towards a new TB diagnostic development project by US-based diagnostic developer Fluxus, Inc., 4 in partnership with Fujirebio, Inc., a developer of clinical diagnostics in Japan,4 and Heidelberg University Hospital in Germany. This project will leverage Fluxus' cutting-edge ultrasensitive detection technology to develop and validate a urine-based TB biomarker lipoarabinomannan (LAM) assay on its automated benchtop immunoassay analyzer. Additionally, the project will design and develop critical components for a portable, ultrasensitive point-of-care (PoC) system that integrates the urine LAM test. This advanced technology will enable rapid, accurate, and accessible diagnosis across a broader patient population, contributing to improved clinical outcomes and reduced transmission. In addition, the GHIT Fund will invest approximately JPY 15.9 million (USD 0.1 million1) in a screening project against Chagas disease and leishmaniasis by Kitasato University, Nagasaki University, University of Tokyo, and Drugs for Neglected Diseases initiative (DNDi). Please refer to Appendix 1 for detailed descriptions on these projects and their development stages. As of March 31, 2025, the GHIT Fund has invested in 36 projects, including 15 discovery projects, 12 preclinical projects, and 9 clinical trials.5 The total amount of investments since 2013 is JPY 38.2 billion (USD 255 million1) (Appendix 2). 1 USD1 = JPY149.53, the approximate exchange rate on March 31, 2025. 2 These awarded projects were selected and approved as new investments from among proposals to RFP2023-002 and RFP2024-001 for the Product Development Platform and the Screening Platform, which were open for applications from June 2023 to July 2024. 3 WHO: 4 Fluxus, Inc. and Fujirebio, Inc. are members of Fujirebio. 5 This number includes projects in the registration phase. The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world's vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases. Appendix 1. Project Details ID: G2023-204 ID: S2024-122 *All amounts are listed at an exchange rate of USD1 = JPY149.53, the approximate exchange rate on March 31, 2025. Appendix 2. Investment Overview (as of March 31, 2025) Investments to date Total investments: 38.2 billion yen (USD 255 million1) Total invested projects: 136 (36 active projects and 100 completed projects) To learn more about the GHIT Fund's investments, please visit Investment Overview: Portfolio: Advancing Portfolio: Clinical Candidates: For more information, contact: Katy Lenard at +1-301-280-5719 or [email protected] Mina Ohata at +81-36441-2032 or [email protected] SOURCE GHIT Fund WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

International research team aims to develop better understanding of Alzheimer’s disease and dementia in diverse populationsMENLO PARK, Calif. and GENEVA, Switzerland , April 22, 2025 (GLOBE NEWSWIRE) -- The Davos Alzheimer’s Collaborative (DAC), a global initiative to prevent Alzheimer’s disease and improve brain health, today announced that PacBio (NASDAQ: PACB), a leader in high-quality, highly-accurate long-read sequencing platforms, will be a technology partner to its North African Dementia Registry (NADR) project. Spearheaded by DAC, this effort brings together The Institute of Global Health and Human Ecology (I-GHHE) at The American University in Cairo (AUC) and UCL Queen Square Institute of Neurology, University College London (UCL), and aims to develop a high-quality, comprehensive multi-omics dataset to advance the research community’s understanding of the genetics of Alzheimer’s disease and dementias in diverse global populations. This collaboration represents a significant step toward addressing the underrepresentation of North African populations in dementia research. The NADR is the first dementia-focused registry of its kind in North Africa. The DAC-led effort with AUC and UCL will enable biosamples collection, cognitive assessments and digital phenotyping. By generating a comprehensive multi-omics dataset, researchers will have the opportunity to explore new insights into the genetic and environmental factors contributing to Alzheimer's disease and dementias. This initiative will leverage PacBio's advanced sequencing technology to generate genetic insights that can guide future research, prevention, and treatment efforts. Vaibhav Narayan, Executive Vice President at Davos Alzheimer’s Collaborative, highlighted the global impact of this effort. "This collaboration will bolster our understanding of Alzheimer’s disease in a region characterized by remarkable genetic diversity. Over time, these insights will inform locally relevant prevention and intervention strategies for communities often overlooked in global research efforts." "We are proud to partner with DAC, AUC, and UCL on this important project to advance our understanding of the genetics of Alzheimer’s disease, and hopefully help researchers identify new diagnostic tools and therapeutic solutions," said Neil Ward, Vice President and General Manager of EMEA at PacBio. "Our long-read sequencing technology is uniquely suited to deliver the high-quality genomic data needed to explore the complex genetic landscape of Alzheimer’s disease. This initiative aligns with our commitment to enabling genomic discoveries that improve human health worldwide." Dr Mie Rizig, UCL NADR lead and clinical senior research fellow in the Department of Neuromuscular Diseases at UCL Queen Square Institute of Neurology, emphasized the critical need for robust datasets in dementia research. "Addressing the global challenge of dementia requires diverse, high-quality datasets. With PacBio's technology and workflows, we can accelerate our understanding of the genetic architecture of populations in North Africa and uncover novel biomarkers and potential therapeutic targets." "With a population exceeding 110 million, Egypt serves as a unique bridge between Africa and the Middle East, offering a rich tapestry of genetic and cultural heritage," said Mohamed Salama, author of AL-SEHA, AUC-NADR lead, and professor at AUC's I-GHHE. "This collaboration not only promises to benefit the Egyptian population but also aims to advance our collective understanding of dementia in the region and beyond." Data generated through this collaboration will be made accessible via the Alzheimer’s Disease Data Initiative (ADDI) platform, which provides controlled access to researchers worldwide to support continued innovation in Alzheimer’s disease research. DAC is bringing together a diverse array of partners to foster collaboration and innovation to enhance our capabilities and drive meaningful outcomes that address the challenges and opportunities in brain health. Together, we are committed to building a future that benefits all stakeholders involved. About the Davos Alzheimer’s Collaborative The Davos Alzheimer's Collaborative (DAC) is a pioneering worldwide initiative to prevent Alzheimer’s disease and improve brain health, seeking to mirror the success of global efforts against infectious diseases such as HIV/AIDS, Covid, and Malaria. DAC is extending global research beyond its current focus on traditional Western European ethnic populations into the highly diversified populations of the Global South, where the vast majority of those with Alzheimer’s live. By introducing lower-cost screening and diagnostic tools as well as new treatment and prevention modalities in primary care and community health settings, DAC is driving implementation of health system solutions that are appropriate for worldwide application. DAC also promotes the vital importance of brain health throughout the lifespan by addressing cardiometabolic and lifestyle factors, especially in early and mid-life. Absent effective action at scale around the world, by 2050, more than 150 million families and half a billion people will be personally impacted by dementia, creating a social, financial, economic, and global security disaster of historic proportions. DAC was launched in Davos in 2021 by the World Economic Forum and the Global CEO Initiative on Alzheimer's Disease. For more information, please visit: davosalzheimerscollaborative.org. About The American University in Cairo (AUC) and the Institute of Global Health and Human Ecology (I-GHHE) Founded in 1919, The American University in Cairo (AUC) is a leading English-language, American-accredited institution of higher education and center of the intellectual, social, and cultural life of the Arab world. It is a vital bridge between East and West, linking Egypt and the region to the world through scholarly research, partnerships with academic and research institutions and study abroad programs. The University offers 39 undergraduate, 52 master’s and two PhD programs rooted in a liberal arts education that encourages students to think critically and find creative solutions to conflicts and challenges facing both the region and the world. An independent, nonprofit, politically non-partisan, non-sectarian and equal opportunity institution, AUC is fully accredited in Egypt and the United States. Espousing a philosophy of implementation sciences, the Institute of Global Health and Human Ecology (I-GHHE) at AUC capitalizes on talents and resources across the University, including the Biomedical Sciences, Nanotechnology, Biotechnology, and Engineering within the School of Sciences and Engineering (SSE), the community insights of the Social and Behavioral Sciences in the School of Humanities and Social Sciences, the economic and entrepreneurial expertise of the School of Business, and the practical know-how of public policy and administration in the School of Global Affairs and Public Policy. With a holistic approach to health and sustainability, the I-GHHE provides an initial focus on curricula and research in support of Environmental Health, Precision Health and Public Health Policy and Management, inclusive of leadership and emergency management. About UCL – London’s Global University UCL is a diverse global community of world-class academics, students, industry links, external partners, and alumni. Our powerful collective of individuals and institutions work together to explore new possibilities.Since 1826, we have championed independent thought by attracting and nurturing the world's best minds. Our community of more than 50,000 students from 150 countries and over 16,000 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems. The Times and Sunday Times University of the Year 2024, we are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact. We have a progressive and integrated approach to our teaching and research – championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors. For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge. We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today. We are UCL. www.ucl.ac.uk | Read news at www.ucl.ac.uk/news/ | Listen to UCL podcasts on SoundCloud | View images on Flickr | Find out what’s on at UCL Minds About Pacific Biosciences PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. Forward Looking Statements This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, quality or performance of, the benefits or expected benefits of using, PacBio products or technologies, including in connection with the use of PacBio technology in, or that PacBio technology is uniquely suited for, the NADR project intended to study and accelerate advancements to better understand underlying factors contributing to Alzheimer’s disease and dementia; that the NADR results could guide future research, prevention, and treatment efforts or identify new diagnostic tools, biomarkers, therapeutic solutions or potential therapeutic targets; accessibility of data generated during the NADR project through the ADDI platform; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results. These risks include, but are not limited to, risks related to reductions in government funding for research grants or contracts; the impact of U.S. export restrictions and tariffs on the shipment of PacBio products to and sourcing of materials from certain countries; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with general macroeconomic conditions and geopolitical instability. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements, including PacBio’s preliminary unaudited financial information and PacBio’s financial guidance, are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available. Contacts (For DAC) Susan Oliver soliver@davosalzheimerscollaborative.orgPhone: 1-703-216-4078 Contacts (For PacBio) Investors and Media: Todd Friedmanir@pacificbiosciences.com Media:ir@pacificbiosciences.com

In a survey representative of the general U.S. adult population, 1.26 percent of respondents – equivalent to about 3 million people – reported having received a medical diagnosis of babesiosis during their life-time; CDC data imply only about 73,000 people in that category.At the time they replied to the survey, 3.7 percent of respondents – equivalent to about 9.9 million people – reported they had been experiencing fatigue, a common symptom of babesiosis, for six months or longer. WASHINGTON, April 22, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced findings that the actual burden of babesiosis in the United States (U.S.) may be significantly higher than Centers for Disease Control and Prevention (CDC) statistics suggest. Preliminary results of an online survey conducted by the Company showed that nearly 3 million Americans (1.26 percent of the adult population in 2020) may have received a babesiosis diagnosis from a medical practitioner in their lifetime. In contrast, CDC reports 1,834 cases of babesiosis in 2020. Even though this annual number relies on different methodologies and timeframes, and is not directly comparable to the Company’s estimates, the disparity suggests the possibility that babesiosis is significantly underdiagnosed or underreported in existing public health reporting data. The Company believes this may indicate a greater demand for effective treatment than suggested by current CDC statistics. The survey included responses from 6,000 participants selected to match the U.S. adult demographic distribution. Babesiosis is a serious, emerging tick-borne disease often found as a co-infection with Lyme disease. It may be life-threatening in immunocompromised and elderly individuals. An as yet untested medical hypothesis advanced by some prescribing physicians in the Lyme disease community is that persistent Babesia infection contributes to chronic fatigue and other problems. If this is true, millions of Americans with persistent fatigue, a common symptom of babesiosis, may be living with an undiagnosed but potentially treatable illness. The Company commissioned the survey as part of its goal to define the size of the commercial market for babesiosis treatment candidates now in development. It was conducted by Format Analytics, an independent market research agency. The online quantitative survey was conducted among a general adult population sample of 6,000 adults, with demographic variables (gender, age, ethnicity, income) matched to U.S. census data for optimal representation of the U.S. population. Babesiosis was reported as a diagnosed medical condition experienced by 1.26 percent of respondents, implying that 3 million Americans may have experienced babesiosis (1.26 percent of 268 million U.S. residents). Moreover, approximately 17 percent of babesiosis patients reported having experienced a duration of illness of six months or more, implying that at least 570,000 U.S. adults have experienced chronic disease (17 percent of 1.26 percent of 268 million U.S. adults). Another objective of the survey was to estimate what proportion of U.S. residents are currently experiencing fatigue lasting longer than six months (inclusive of those who have received a formal diagnosis of chronic fatigue syndrome/encephalomyelitis). Approximately 3.7 percent of respondents to the survey, equivalent to about 9.9 million Americans per a U.S. adult population of 268 million U.S. adults, reported experiencing chronic fatigue of six months or longer at the time the survey was conducted. Approximately 56 percent of them (representing about 1.9 percent of total respondents) reported having received a formal diagnosis of Chronic Fatigue Syndrome (CFS). In contrast, in a 2021/2022 telephone survey, the CDC found that approximately 1.3 percent of respondents had received a formal diagnosis of CFS. “These survey results, which will be submitted for publication soon, suggest that official statistics may not capture the lived experiences of babesiosis patients in the U.S.,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoffrey Dow. “Infectious disease specialists seeking to treat patients who present with unexplained chronic fatigue should consider babesiosis as a differential diagnosis.” About Babesiosis and ARAKODA® Babesiosis is a rapidly emerging tick-borne disease often found as a co-infection with Lyme disease. Based on Lyme disease insurance claims and Babesia co-infection rates, 60 Degrees surmises that approximately 46,000 Americans are diagnosed with acute (short-term) babesiosis each year. Most people recover within 90 days when treated with standard antimicrobials recommended by the Infectious Diseases Society of America. These treatments are assumed to reduce the number of parasites enough for the immune system to clear the rest. However, in some individuals, Babesia infection may persist for at least a year, or they might recover and then feel unwell again up to two years later. Fatigue is usually the last clinical symptom of babesiosis to resolve. The actual number of people living with chronic or persistent (long-term) Babesia infection in the U.S. has not been described in the scientific literature. Medical literature suggests that ARAKODA (tafenoquine), a medicine licensed and manufactured by 60 Degrees may have the potential to clear Babesia parasites and ease symptoms. The Company is currently running two clinical trials (NCT06207370 and NCT06478641) to confirm these findings. A third study is being planned for people with a presumptive diagnosis of babesiosis and experiencing severe and disabling chronic fatigue (NCT06656351). One of the hypotheses the study will test is that 20 percent of patients entering the study will have a Babesia infection confirmable using commercially available molecular tests. ARAKODA is approved for malaria prophylaxis in the United States under the product name ARAKODA®. The safety of the approved regimen of tafenoquine for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months. ARAKODA has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration (FDA) for such an indication. About 60 Degrees Pharmaceuticals, Inc.60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 27, 2025, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contacts:Sheila A. BurkeSheilaBurke-consultant@60degreespharma.com(484) 667-6330 Investor Contact:Patrick Gaynespatrickgaynes@60degreespharma